Cited by 79Fatty Acid Research and HealthGestational Diabetes Research and ManagementBirth, Development, and Health

Plasma phospholipid n-3 and n-6 polyunsaturated fatty acids in relation to cardiometabolic markers and gestational diabetes: A longitudinal study within the prospective NICHD Fetal Growth Studies

Open access
Zhu, Yeyi, Li, Mengying, Rahman, Mohammad L., Hinkle, Stefanie N., Wu, Jing, Weir, Natalie L., Lin, Yuan, Yang, Huixia +3 more·2019·PLOS Medicine

Abstract

BACKGROUND: Despite dietary recommendations of polyunsaturated fatty acids (PUFAs) for cardiometabolic health, n-3 and n-6 PUFAs and their interplay in relation to diabetes risk remain debated. Importantly, data among pregnant women are scarce. We investigated individual plasma phospholipid n-3 and n-6 PUFAs in early to midpregnancy in relation to subsequent risk of gestational diabetes mellitus (GDM). METHODS AND FINDINGS: Within the National Institute of Child Health and Human Development (NICHD) Fetal Growth Studies-Singleton Cohort (n = 2,802), individual plasma phospholipid n-3 and n-6 PUFAs levels were measured at gestational weeks (GWs) 10-14, 15-26, 23-31, and 33-39 among 107 GDM cases (ascertained on average at GW 27) and 214 non-GDM controls. Conditional logistic regression was used, adjusting for major risk factors for GDM. After adjusting for covariates, individual n-3 eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA) were inversely correlated with insulin-resistance markers, whereas individual n-6 dihomo-gamma-linolenic acid (DGLA) was positively correlated with insulin-resistance markers. At GW 15-26, a standard deviation (SD) increase in total n-3 PUFAs and individual n-3 DPA was associated with a 36% (adjusted odds ratio 0.64; 95% CI 0.42-0.96; P = 0.042) and 33% (0.67; 95% CI 0.45-0.99; P = 0.047) lower risk of GDM, respectively; however, the significance did not persist after post hoc false-discovery rate (FDR) correction (FDR-corrected P values > 0.05). Associations between total n-6 PUFAs and GDM were null, whereas associations with individual n-6 PUFAs were differential. Per SD increase, gamma-linolenic acid (GLA) at GWs 10-14 and DGLA at GWs 10-14 and 15-26 were significantly associated with a 1.40- to 1.95-fold higher risk of GDM, whereas docosatetraenoic acid (DTA) at GW 15-26 was associated with a 45% (0.55; 95% CI 0.37-0.83) lower risk of GDM (all FDR-corrected P values < 0.05). Null associations were observed for linoleic acid (LA) in either gestational window in relation to risk of GDM. Women with high (≥median) n-3 PUFAs and low (<median) n-6 PUFAs levels had a 64% (95% CI 0.14-0.95; P value = 0.039) lower risk of GDM versus women with low n-3 and high n-6 PUFAs. Limitations include the inability to distinguish between exogenous and endogenous influences on circulating PUFA levels and the lack of causality inherent in observational studies. CONCLUSIONS: Our findings may suggest a potential role of primarily endogenously metabolized plasma phospholipid n-6 PUFAs including GLA, DGLA, and DTA in early to midpregnancy in the development of GDM. Null findings on primarily diet-derived n-3 EPA and DHA and n-6 LA do not provide strong evidence to suggest a beneficial role in prevention of GDM, although not excluding the potential benefit of EPA and DHA on glucose-insulin homeostasis given the inverse associations with insulin-resistance markers. Our findings highlight the importance of assessing individual circulating PUFAs to investigate their distinct pathophysiologic roles in glucose homeostasis in pregnancy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.1002910

Cites

60 of 61 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Omega-6 consumption is associated with increased GDM risk.

    “However, a longitudinal study reported increased GDM risk with omega-6 consumption [117].”

    From Medical Nutrition Therapy for Women with Gestational Diabetes: Current Practice and Future Perspectives (2025) · cites this paper as [117]

    The Results section reports higher GDM risk with higher plasma levels of two individual omega-6 fatty acids, GLA and DGLA. But it reports no significant association for total plasma omega-6 fatty acids, and the Discussion says the primarily diet-derived omega-6 fatty acid LA was not significantly associated with GDM risk. The study measured circulating fatty acids, not omega-6 consumption, so the citation does not support the claim as phrased. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Zhu, Y., Li, M., Rahman, M. L., Hinkle, S. N., Wu, J., Weir, N. L., Lin, Y., Yang, H., Tsai, M. Y., Ferrara, A., & Zhang, C.
Affiliations
  • Kaiser Permanente (US)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (US)
  • Harvard University (US)
  • Glotech (United States) (US)
  • University of Minnesota (US)
  • Indiana University Indianapolis (US)
  • Peking University First Hospital (CN)
Corresponding author
  • Zhu, Yeyi
  • Zhang, Cuilin
Venue
PLOS Medicine
Published
2019-09-13
Volume
16
Issue
9
Pages
e1002910
ISSN
  • 1549-1277 (ISSN-L)
  • 1549-1676
OpenAlex
W2972623323
Cited by
79
References
60
Citations by year
2026: 8 · 2025: 11 · 2024: 7 · 2023: 17 · 2022: 12 · 2021: 14 · 2020: 9
FWCI
6.66
Type
journal article
Language
en
Open access
Locations
  • PLoS Medicine (publishedVersion, public-domain)
  • Europe PMC (PubMed Central) (publishedVersion, public-domain)
  • PubMed Central (publishedVersion, public-domain)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (HHSN275200800013C, HHSN275200800002I, HHSN27500006, HHSN275200800003IC, HHSN275200800014C, HHSN275200800012C, HHSN275200800028C, HHSN275201000009C, and HHSN275201000001Z)
  • National Institutes of Health (NIH) Building Interdisciplinary Research Careers in Women’s Health Program (5K12HD052163)
  • National Institute of Diabetes and Digestive and Kidney Diseases (K01DK120807)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Birth, Development, and Health
Keywords
gestational diabetes mellitus, plasma phospholipid fatty acids, omega-3 fatty acids, omega-6 fatty acids, eicosapentaenoic acid, docosahexaenoic acid, docosapentaenoic acid, gamma-linolenic acid, dihomo-gamma-linolenic acid, insulin resistance, cardiometabolic risk, pregnancy
MeSH terms
Adolescent, Adult, Blood Glucose, Female, Gestational Age, Humans, Insulin, Insulin Resistance, Longitudinal Studies, Nutritional Status, Phospholipids, Pregnancy, Prospective Studies, Risk Factors, Biomarkers, Fatty Acids, Omega-3, Case-Control Studies, Diabetes, Gestational, Risk Assessment, Maternal Nutritional Physiological Phenomena, Fatty Acids, Omega-6, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review